Navigation Links
Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
Date:3/27/2009

terially from stated expectations. For example, there can be no assurance that results or trends observed in pre-clinical studies will be reproduced in subsequent studies, that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, and our ability to obtain necessary funding, regulatory approvals and expected qualifications, our limited experience in the development, testing and marketing of complex biologics and therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such products or proposed products will be successful or completed within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
5. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
6. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
7. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
8. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
9. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
10. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
11. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... entered into a definitive distribution agreement with Patterson Veterinary ... and promote the full line of Abaxis veterinary products ...
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... 9, 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and ... 767905/014 and,provided an update on the clinical ... Phase 3, double blind, placebo-controlled (12,month) study, ... and,tolerability of alvimopan 0.5 mg twice daily ...
... Educate on Good,Diabetes Management and How to Reduce ... 10, 2007 /PRNewswire/ -- A first-of-its-kind,report looking at ... shows that an estimated three out of five ... least one of the other,serious health problems commonly ...
Cached Medicine Technology:GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
(Date:10/2/2014)... (PRWEB) October 02, 2014 BamboofloorChina.com is ... its products have won great appreciation from the global ... is working hard to make more excellent items. All ... ready to help all clients. , The company ... panels to its website. Furthermore, the company’s marketing ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... personality style and prolonged stress may have a heightened ... Tracking 800 women over nearly four decades, Swedish scientists ... moody -- which they defined as neurotic -- and ... Alzheimer,s compared to women scoring lowest in these traits. ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... a major highway may raise your risk for high blood ... postmenopausal women, those who lived within 109 yards of a ... high blood pressure than women living at least half a ... study highlight the importance of our physical environment on our ...
(Date:10/2/2014)... By Amy Norton HealthDay ... adults who have trouble smelling the roses -- literally -- may ... new research suggests. In a study of over 3,000 older ... as rose, orange and peppermint were more than three times as ... a sharp sense of smell. In fact, anosmia -- the ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... Sept. 2 A survey of emergency medical services (EMS) ... of workplace safety cultureproviding a tool that might point to ... of Pittsburgh School of Medicine. The study ... Prehospital Emergency Care and now available online, analyzed survey ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Sept. ... mentally stimulating activities have pros and cons when it comes ... prior research, the study finds that such mental activity may ... But folks who loved these pursuits actually displayed a ...
... Sept. 1 (HealthDay News) -- A new study is linking ... non-fatal heart attacks and stroke, although taking the drug did not ... history of heart problems. The finding is stirring mixed reactions ... was funded by Meridia,s maker, Abbott, the findings are generally in ...
... September issue of the Journal of the American Geriatrics ... have a greater risk for dementia than Veterans without PTSD, ... Exposure to life threatening events, like war, can cause PTSD, ... symptoms such as avoiding things or people that remind a ...
... Engineering at Harvard and from Boston University have discovered ... microscopic forms of lifebacteria. Their findings appear in ... studying the development of antibiotic-resistant strains of bacteria, the ... doses of antibiotics are those in which a few ...
... Lee Phillips HealthDay Reporter , WEDNESDAY, Sept. ... inflammation in those with lupus, but the anti-clotting drug ... disease, a new study suggests. Platelets, which are ... clotting, are suspected to be involved in lupus, explained ...
Cached Medicine News:Health News:Safety cultures in EMS agencies vary widely, Pitt study finds 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 3Health News:Diet Pill Meridia Ups Heart Attack Risk: Study 2Health News:Diet Pill Meridia Ups Heart Attack Risk: Study 3Health News:Pivotal study finds link between PTSD and dementia 2Health News:New research finds evidence of charitable behavior in bacteria 2Health News:Overactive Blood Platelets May Play Role in Lupus 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... The AFX (Air Fluid eXchange) ... lens designed for use in ... to its use as a ... the low profile and sutureless ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
Medicine Products: